Lexicon Touts Analyses From Two Phase 3 Trials Of Its Heart Failure Drug

Lexicon Pharmaceuticals Inc LXRX has presented additional analyses from SOLOIST and SCORED Phase 3 trials evaluating heart failure candidate sotagliflozin, a dual SGLT1 & SGLT2 inhibitor.
Data were presented at the ESC Congress 2021 - The Digital Experience.
In the SOLOIST trial, sotagliflozin was evaluated against the standard of care in 1,222 Type 2 diabetes patients who had been hospitalized with worsening heart failure.
In the trial, the drug posted a 33% absolute risk reduction on an endpoint that combined cardiovascular death and hospitalizations or urgent office visits for heart failure.
Investigators noticed the benefits within one month of treatment.
Researchers tested the drug against the standard of care in certain patients with Type 2 diabetes, chronic kidney disease, and cardio risks in the SCORED trial. It enrolled 10,584 patients.
Sotagliflozin posted a 26% risk reduction on the same composite endpoint, and investigators saw benefits within three months.
Lexicon had previously released the SOLOIST and SCORED results, but new analyses from sotagliflozin's higher dose (400 mg) were associated with a more pronounced risk reduction and no new safety concerns.
Price Action: LXRX shares are up 5.19% at $3.65 during the market session on the last check Monday.